A Surprising Liver Condition Found in Type 2 Diabetes: What You Should Know
Glycogenic hepatopathy, a rare liver condition traditionally linked to Type 1 diabetes, has been discovered in people with Type 2 diabetes. A new case report shows this condition is reversible with proper diabetes management.
Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.
Key takeaways
- Glycogenic hepatopathy (GH) is a rare, reversible condition where glycogen builds up in liver cells, causing an enlarged liver and elevated liver enzymes
- While traditionally associated with poorly controlled Type 1 diabetes, GH can occur in Type 2 diabetes, even without severe high blood sugar
- GH may overlap with another liver condition called MASLD (metabolic dysfunction-associated steatotic liver disease) in people with Type 2 diabetes
- In this case, improved blood sugar control led to reversal of the liver changes, including significant drops in liver enzyme levels
What Is Glycogenic Hepatopathy?
Glycogenic hepatopathy (GH) is an uncommon cause of liver enlargement and elevated liver enzymes. It occurs when the liver accumulates too much glycogen—the stored form of glucose. The condition is usually reversible, meaning it can improve when the underlying cause is addressed.
For decades, doctors have primarily associated GH with Type 1 diabetes that is poorly controlled. However, researchers are increasingly recognizing that this condition can also develop in people with Type 2 diabetes, even when blood sugar levels are not severely elevated.
A Real-World Case: Type 2 Diabetes and Liver Changes
A case report published in SAGE Open Medical Case Reports describes a woman in her late 20s with obesity and newly diagnosed Type 2 diabetes. Despite a hemoglobin A1C level of 7.0%—considered close to target—she had unexplained high liver enzymes and an enlarged liver visible on ultrasound.
A liver biopsy revealed glycogen accumulation consistent with GH, along with fatty changes and mild scarring. This finding was surprising because her blood sugar was not severely out of control, and she had no signs of diabetic emergencies like ketoacidosis.
How Treatment Changed the Picture
After starting semaglutide, a diabetes and weight-loss medication, the woman's condition improved significantly over four months. Her hemoglobin A1C dropped from 7.0% to 6.0%, she lost weight, and her liver enzymes fell dramatically—with one enzyme dropping from 363 to 73 U/L and another from 209 to 47 U/L.
These improvements happened together, supporting the idea that better blood sugar control and weight loss can reverse glycogenic hepatopathy. However, researchers cannot fully separate which factor—reduced glycogen buildup or improvement in the fatty liver disease—contributed most to the liver enzyme improvements.
Why This Case Matters
This case highlights an important lesson: glycogenic hepatopathy is not limited to people with Type 1 diabetes or only those with severely uncontrolled blood sugar. The condition can occur in Type 2 diabetes and may exist alongside other liver problems like metabolic dysfunction-associated steatotic liver disease (MASLD).
If you have diabetes and your doctor finds elevated liver enzymes or an enlarged liver, it does not necessarily mean severe or permanent damage. Work with your healthcare team to understand what is happening and how better diabetes management might help. As this case shows, the liver condition can improve when blood sugar control and overall metabolic health improve.
Evidence label
Source: SAGE open medical case reports. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.
Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.
From Type1Cure
Related reading
More evidence-labeled coverage across the Type1Cure library.
- Research summaryDiagnosis & Early DetectionA Simple Blood Test May Help Doctors Assess How Severe Your DKA IsPubMed indexed literature
- Research summaryDiagnosis & Early DetectionA New Approach to Finding Type 1 Diabetes Early: Testing During Routine CheckupsPubMed indexed literature
- Research summaryDiagnosis & Early DetectionSingle Autoantibody: What It Means When Your Child Tests Positive for One Type 1 MarkerPubMed indexed literature
- Research summaryDiagnosis & Early DetectionKetosis-Prone Type 2 Diabetes: New Clues to an Immune Mix-UpPubMed indexed literature
- Research summaryDiagnosis & Early DetectionWhy Screening for Type 1 Diabetes Before Symptoms MatterPubMed indexed literature
- Research summaryDiagnosis & Early DetectionTesting for Type 1 Before Symptoms Appear: What a Real-World Pilot LearnedPubMed indexed literature